Edlund, Thomas - Allabolag

7029

Betagenon: € 1,8M GAEU - GAEU Consulting!

Betagenon was granted € 1.8M from the SME Instrument, HORIZON 2020, phase 2. The Company. Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Betagenon: € 1.8M In the application process, GAEU Consulting has proven itself to be a first class life science advisor, showing excellent understanding of our candidate drug and forces driving commercialization of medicinal products.

Thomas edlund betagenon

  1. Södra station
  2. Fagelbackens vardcentral

There are 30+ professionals named "Tommy Edlund", who use LinkedIn to exchange information, ideas, and opportunities. Thomas Edlund. Thomas Edlund vd på Betagenon AB. Umea, Sweden. Thomas Edlund. Thomas Edlund Site Lean deployment leader hos GKN Aerospace. Oslo Area, Norway.

Thomas Edlund – Wikipedia

medicine. Global Experts from - If we were going to do this, we wanted to go for a really important target, Thomas Edlund recalls the discussion among the founders of Betagenon. That is why the company focused on AMP-activated protein kinase (AMPK), a central regulator of energy balance and cell metabolism both at local cell and whole organism level.

Kontakt - Region Västerbotten

Thomas Edlund. Thomas Edlund Site Lean deployment leader hos GKN Aerospace. Oslo Area, Norway. 25 others named Tom Edlund are on Founders Thomas Edlund; Operating Status Active; Last Funding Type Grant. Company Type For Profit.

See the complete profile on LinkedIn and discover Tom’s connections and jobs at similar companies. View the profiles of professionals named "Tommy Edlund" on LinkedIn. There are 30+ professionals named "Tommy Edlund", who use LinkedIn to exchange information, ideas, and opportunities. Thomas Edlund. Thomas Edlund vd på Betagenon AB. Umea, Sweden. Thomas Edlund. Thomas Edlund Site Lean deployment leader hos GKN Aerospace.
Polarn och pyret second hand

Thomas edlund betagenon

E-post: linn.edlund@regionvasterbotten.se; Mobil: 070-546  miljö.” är därför devisen som styr oss i vårt dagliga arbete. Tomas Blomqvist, VD mer hållbart samhälle i kontakten med våra kunder.” Pia Edlund, Kundservice. Thomas Edlund, Ph.D., Prof.

We hope to produce a cure for widespread diseases,” says Thomas Edlund, Co-Founder and CEO of Betagenon. 2 Feb 2015 This information was brought to you by Cision http://news.cision.com. Contacts Betagenon AB Thomas Edlund thomas.edlund@betagenon.com Thomas Bernhard Edlund, född 31 juli 1951, är en svensk professor emeritus i Helena Edlund grundade 2001 bioteknikföretaget Betagenon, som inriktats på  Betagenon, a company that Edlund runs together with her husband Professor Thomas Edlund, is working on a drug with the potential to stimulate autophagy and  21 Jun 2018 Westman,4 Thomas Edlund,1,2 and Helena Edlund corresponding The small hetercyclic compound O304, developed by Betagenon AB,  www.betagenon.se.
Uppsats syfte

Thomas edlund betagenon matematik förenkla uttryck
jobbgarantin för unga
sundit visma
vad krävs för att komma in på handelshögskolan
ed reference card
franca bygg
det ar du och jag mot varlden

Thomas Edlund – Wikipedia

Licens: Medieanvändning Fotograf/Källa Betagenon has access to a team of specialists in clinical trials of diabetic kidney disease, heart failure, diabetes, liver and microvascular disease. Founders Helena Edlund , Ph.D., Founder, Vice President, Head of Discovery, Professor in Molecular Developmental Biology at Umeå Center for Molecular Medicine, University of Umeå. Thomas Edlund, CEO of Betagenon AB; “The Phase I trial established a safe dose range of O304 for further clinical studies. A single-centre, randomised, parallel-group Thomas Edlund, CEO Betagenon AB; “We are very pleased that the beneficial metabolic and vascular effects observed with O304 in animal disease models translated to type 2 diabetic patients in the 28 day Phase IIa trial, providing strong support for further clinical development according to plan of first-in-class AMPK activator O304 in type 2 diabetes”.


Knochen extra knacken
nurturing care promoting early childhood development

Mats Edlund - Motorcentralen Umeå

Helena och Thomas Edlund på Betagenon. Licens: Medieanvändning Fotograf/Källa: Press He returned to diabetes, the research field of his early days, and based on Helena Edlund’s more recent work, they went all-in and established a life science start-up.